Genomics

Dataset Information

0

SubclonalHeterogeneity_MuTect-TITAN_CNVs - samples

ABSTRACT: CNA calls generated using the MuTect-TITAN-PhyloWGS from the CPC-GENE Subclonal Heterogeneity study

PROVIDER: EGAD00001004404 | EGA |

REPOSITORIES: EGA

Json Xml
altmetric image

Publications

Genomic hallmarks of localized, non-indolent prostate cancer.

Fraser Michael M   Sabelnykova Veronica Y VY   Yamaguchi Takafumi N TN   Heisler Lawrence E LE   Livingstone Julie J   Huang Vincent V   Shiah Yu-Jia YJ   Yousif Fouad F   Lin Xihui X   Masella Andre P AP   Fox Natalie S NS   Xie Michael M   Prokopec Stephenie D SD   Berlin Alejandro A   Lalonde Emilie E   Ahmed Musaddeque M   Trudel Dominique D   Luo Xuemei X   Beck Timothy A TA   Meng Alice A   Zhang Junyan J   D'Costa Alister A   Denroche Robert E RE   Kong Haiying H   Espiritu Shadrielle Melijah G SM   Chua Melvin L K ML   Wong Ada A   Chong Taryne T   Sam Michelle M   Johns Jeremy J   Timms Lee L   Buchner Nicholas B NB   Orain Michèle M   Picard Valérie V   Hovington Helène H   Murison Alexander A   Kron Ken K   Harding Nicholas J NJ   P'ng Christine C   Houlahan Kathleen E KE   Chu Kenneth C KC   Lo Bryan B   Nguyen Francis F   Li Constance H CH   Sun Ren X RX   de Borja Richard R   Cooper Christopher I CI   Hopkins Julia F JF   Govind Shaylan K SK   Fung Clement C   Waggott Daryl D   Green Jeffrey J   Haider Syed S   Chan-Seng-Yue Michelle A MA   Jung Esther E   Wang Zhiyuan Z   Bergeron Alain A   Dal Pra Alan A   Lacombe Louis L   Collins Colin C CC   Sahinalp Cenk C   Lupien Mathieu M   Fleshner Neil E NE   He Housheng H HH   Fradet Yves Y   Tetu Bernard B   van der Kwast Theodorus T   McPherson John D JD   Bristow Robert G RG   Boutros Paul C PC  

Nature 20170109 7637

Prostate tumours are highly variable in their response to therapies, but clinically available prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 whole-genome sequences and 277 additional whole-exome sequences from localized, non-indolent prostate tumours with similar clinical risk profiles, and carried out RNA and methylation analyses in a subset. These tumours had a paucity of clinically actionable single nucleotide variants, unlike those seen in metastat  ...[more]

Similar Datasets

Genomics SubclonalHeterogeneity_regions_MuTect-TITAN_CNVs - samples
| EGAD00001004442 | EGA
Genomics SubclonalHeterogeneity_MuTect-TITAN_SNVs - samples
| EGAD00001004401 | EGA
Genomics SubclonalHeterogeneity_MuTect-Battenberg_CNVs - samples
| EGAD00001004403 | EGA
Genomics SubclonalHeterogeneity_regions_MuTect-TITAN_SNVs - samples
| EGAD00001004433 | EGA
Genomics SubclonalHeterogeneity_regions_SomaticSniper-TITAN_CNVs - samples
| EGAD00001004440 | EGA
Genomics SubclonalHeterogeneity_regions_SomaticSniper-Battenberg_CNVs - samples
| EGAD00001004441 | EGA
Genomics SubclonalHeterogeneity_regions_MuTect-Battenberg_CNVs - samples
| EGAD00001004443 | EGA
Genomics SubclonalHeterogeneity_MuTect-Battenberg_SNVs - samples
| EGAD00001004400 | EGA
Genomics SubclonalHeterogeneity_SomaticSniper-Battenberg_CNVs - samples
| EGAD00001004405 | EGA
Genomics SubclonalHeterogeneity_regions_SomaticSniper-TITAN_SNVs - samples
| EGAD00001004431 | EGA